Liver cancer patients have high diabetes prevalence

NEW YORK (Reuters Health) - Patients with hepatocellular carcinoma (HCC) have a significantly higher prevalence of type 2 diabetes mellitus (DM) compared to the general population, according to findings from a case-control study conducted in Italy.

“The association of type (DM2) … with hepatocellular carcinoma (HCC) has been long suspected,” Dr. Valter Donadon, at Pordenone Hospital, and co-authors note in the October 7 issue of the World Journal of Gastroenterology. “However, the temporal relationship between onset of diabetes and development of HCC, and the clinical and metabolic characteristics of patients with DM2 and HCC have not been well examined.”

Their study included 465 consecutive Caucasian HCC patients and 490 age- and sex-matched controls.

Overall, 145 hepatocellular carcinoma patients (31 percent) and 62 control cases (13 percent) had type 2 diabetes (odds ratio 3.1). Moreover, the authors note, diabetes had been diagnosed at least 6 months prior to the diagnosis of hepatocellular carcinoma in 84 percent of cases, suggesting that diabetes may be a cause rather than a consequence of liver cancer.

Men with DM and HCC were more likely to be treated with insulin than male diabetics in the control group (38 percent vs 18 percent, p = 0.009), leading the researchers to recommend “close surveillance for HCC in patients with chronic liver disease and DM2, particularly (among) males and (those) treated with insulin.”

They also advise that metabolic control be attempted with insulin-sensitizers, such as metformin and glitazones, in preference to insulin or oral secretogogues.

World J Gastroenterol 2008;14:5695-5700.


Related Posts:

NEW YORK (Reuters Health) - The risk of a rare form of liver cancer called intrahepatic cholangiocarcinoma, which occurs in the bile ducts of the liver, is significantly elevated in individuals who are infected with hepatitis C virus (HCV), according to a large “case-control” study of US veterans. HCV-infected individuals are also at increased risk for

Full Post: Hepatitis C ups liver cancer risk, study confirms

NEW YORK (Reuters Health) - Drugs used to control diabetes may lower the risk of prostate cancer, investigators at the University of Tampere in Finland report. “Recent studies have reported a decreased prostate cancer risk for diabetic men, although the evidence is controversial,” Dr. Teemu J. Murtola and colleagues note in the American Journal of Epidemiology.

Full Post: Diabetes drugs tied to lower prostate cancer risk

NEW YORK (Reuters Health) - Good metabolic control and intensive insulin treatment doesn’t normalize the onset of menstruation, which is usually delayed in girls with type 1 diabetes compared with girls without the disease, study findings confirm. Dr. Paolo Pozzilli, at Universita Campus Bio-Medico, in Rome, and colleagues compared the age at onset of menstruation among

Full Post: Diabetes control doesn’t normalize menstruation

NEW YORK (Reuters Health) - Surgical removal of the kidney — a procedure known as nephrectomy — improves survival in patients with locally advanced renal cell carcinoma, the most common form of kidney cancer. Dr. Pierre I. Karakiewicz from University of Montreal and colleagues determined survival rates for 43,143 patients treated with nephrectomy for advanced renal

Full Post: Surgery improves kidney cancer survival: study

By Will Dunham WASHINGTON (Reuters) - Cancer, the world’s No. 2 killer, is even more lethal for people with diabetes, U.S. researchers said on Tuesday. People with diabetes who get cancer are about 40 percent more likely to die in the years following the diagnosis than cancer patients who are not diabetics, according to research published in

Full Post: Cancer even deadlier for people with diabetes

Site Navigation

Most Read